Clinical Trials Related to Primary Peritoneal Cancer

Related studies linked through entity extraction aliases.

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Status: TERMINATED
Phase: PHASE1

Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study

Status: COMPLETED
Phase: N/A

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer

Status: COMPLETED
Phase: PHASE1

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Status: COMPLETED
Phase: PHASE2

Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer

Status: COMPLETED
Phase: PHASE1

Autologous OC-L Vaccine and Ovarian Cancer

Status: TERMINATED
Phase: PHASE1

p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Status: UNKNOWN
Phase: PHASE2

Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission

Status: COMPLETED
Phase: PHASE1

Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Status: TERMINATED
Phase: PHASE2

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Status: COMPLETED
Phase: PHASE1

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Status: TERMINATED
Phase: PHASE1/PHASE2

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

Status: COMPLETED
Phase: PHASE1/PHASE2

PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer

Status: COMPLETED
Phase: PHASE2

"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies

Status: WITHDRAWN
Phase: PHASE1/PHASE2

Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer

Status: TERMINATED
Phase: NA

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Status: COMPLETED
Phase: PHASE2

A Study LY2228820 for Recurrent Ovarian Cancer

Status: COMPLETED
Phase: PHASE1/PHASE2